Quote this publication Share Print

FLUARIXTETRA, quadrivalent seasonal influenza vaccine

INFECTIOUS DISEASE - New indication
Opinions on drugs - Posted on Dec 18 2018

Reason for request

Extension of indication

»  FLUARIXTETRA now has MA for the prevention of seasonal influenza in infants and children, aged from 6 to 35 months.

»  In this population, its efficacy and safety profile is comparable overall to that of trivalent influenza vaccines.

»  This vaccine targets populations at a risk of severe forms of influenza.


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-